Diffusion Pharmaceuticals

140 articles about Diffusion Pharmaceuticals

• Diffusion Pharmaceuticals, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference

  3/4/2021

  Diffusion Pharmaceuticals Inc., an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, announced that Robert J. Cobuzzi, Ph.D., CEO of Diffusion, will present at the H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.

• Diffusion Pharmaceuticals Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares of Common Stock

  2/18/2021

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)  (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies to deliver oxygen to areas of the body where it is needed most, announced today that the underwriter of its previously announced underwritten public offering has exercised in full its option to purchase an additional 4,390,244 shares of its common stock at a price to the public of $1.025 per share

• Diffusion Pharmaceuticals Announces Closing of $30 Million Bought Deal Offering of Common Stock

  2/17/2021

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)  (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies to deliver oxygen to areas of the body where it is needed most, announced today the closing of its previously announced underwritten public offering of 29,268,294 shares of its common stock at a price to the public of $1.025 per share,

• Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 PatientsNo Dose Limiting Toxicities or Serious Adverse Events Observed in Dosing Regimen Previously Untested in Clinical Trial Setting

  2/16/2021

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)  (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies to deliver oxygen to areas of the body where it is needed most, today announced completion and topline data from the open-label, Phase 1b clinical trial of its novel, diffusion-enhancing therapeutic, trans sodium crocetinate (“TSC”), in hospitalized COVID-19 patients with confirmed hypoxemia

• Diffusion Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $30 Million

  2/12/2021

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company developing novel therapies to enhance the diffusion of oxygen to tissues with low oxygen levels, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 29,268,294 shares of common stock of the Company

• Diffusion Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock

  2/11/2021

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN)  (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company developing novel therapies to enhance the diffusion of oxygen to tissues with low oxygen levels, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 9,756,098 shares of common stock

• Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference

  1/11/2021

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that the Company is participating in the H.C. Wainwright BioConnect 2021 Conference being held virtually January 11-14, 2021.

• Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates

  11/12/2020

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or the “Company”) today reported financial results for the three and nine months ended September 30, 2020

• Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer

  10/19/2020

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced the appointment of Christopher D. Galloway, M.D. to Chief Medical Officer, effective immediately. Dr. Galloway will report to Robert Cobuzzi, Ph.D., Diffusion’s Chief Executive Officer. Dr. Galloway is board certified in Emergency Medicine and will assume responsibility of leading the Company’s product development efforts, including clinical

• Diffusion Pharmaceuticals Strengthens Management Team with Appointment of William Elder as General Counsel and Corporate Secretary

  9/24/2020

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”) today announced the appointment of William Elder, J.D., to the position of general counsel and corporate secretary, effective immediately. He will report to Robert Cobuzzi, Ph.D., chief executive officer of Diffusion.

• 

  Clinical Catch-Up: September 7-11

  9/14/2020

  It was a busy week for clinical trial updates. Here’s a look.

• Diffusion Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Virtual Global Investment Conference

  9/11/2020

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced its management will present at the H.C. Wainwright 22nd Annual Global Investment Conference to be held virtually on September 14-16, 2020. Robert Cobuzzi, Ph.D., chief executive officer, will present a corporate overview of the Company on Tuesday, September 15th

• 

  BioSpace Movers & Shakers, Sept. 11

  9/11/2020

  Biopharma and life sciences companies bolster their leadership teams and boards with these Movers & Shakers.

• Diffusion Pharmaceuticals Doses First Two Patients with TSC in COVID-19 Clinical TrialTwenty-four patient Phase 1b safety and tolerability study initiated in Romania

  9/10/2020

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”) today announced dosing of the first two patients in the Company’s open-label Phase 1b lead-in trial of its novel, oxygen-enhancing therapeutic, trans sodium crocetinate (“TSC”), in 24 hospitalized COVID-19 patients. In addition to evaluating the safety and tolerability of TSC, this trial will collect preliminary data on TSC’s effects on arterial blood oxygenat

• Diffusion Pharmaceuticals Names Director Dr. Robert Cobuzzi as President and Chief Executive Officer

  9/8/2020

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that Robert (“Bob”) J. Cobuzzi Jr., Ph.D., who has served as a member of the Company’s Board of Directors since January 2020, will succeed David G. Kalergis as President and Chief Executive Officer effective immediately.

• 

  BioSpace Movers & Shakers, Sept. 4

  9/4/2020

  Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.

• Diffusion Pharmaceuticals Appoints Jane H. Hollingsworth to its Board of DirectorsRomanian Regulatory Approval Received to Begin Phase 1b COVID-19 Clinical Trial

  9/1/2020

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to deliver oxygen to the areas where it is needed most, today announced the appointment of Jane H. Hollingsworth to its board of directors, effective immediately.

• Diffusion Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business UpdateContinues global clinical development of TSC for the treatment of COVID-19

  8/10/2020

  Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to deliver oxygen to the areas where it is needed most, today reported financial results for the three and six months ended June 30, 2020 and provided a business update. Highlights from the second quarter of 2020 and recent w

• Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b/2b COVID-19 Clinical Program with TSC

  7/27/2020

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “Company”), a biotechnology company developing novel therapeutics for the treatment of unmet medical needs, today announced receipt of guidance from the U.S. Food and Drug Administration (FDA) on the Company’s recently-filed Investigational New Drug (IND) application

• Diffusion Pharmaceuticals Files IND for International Phase 1b/2b COVID-19 Clinical Program With TSC

  7/7/2020

  Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “Company”), a biotechnology company developing novel therapeutics for the treatment of unmet medical needs, today announced the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for trans sodium crocetinate (TSC) in COVID-19 patients